

28th July 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (November 2025 – April 2026)?

• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	34
• Natalizumab (Tysabri and Tyruko)	0

Please note that East Sussex Healthcare NHS Trust only provides treatment with Dimethyl Fumarate. All the other treatment regimens listed above are provided by University Hospitals Sussex NHS Foundation Trust (UHSussex).

1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in May 2025 to October 2025 AND November 2025-April 2026)

• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	34
• Natalizumab (Tysabri and Tyruko)	0

2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (November 2025 – April 2026)?

25.

2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

• Ocrevus (ocrelizumab) IV (300mg/30ml)	0
• Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	0
• Kesimpta (ofatumumab)	0
• Briumvi (ublituximab)	0
• Mavenclad (cladribine)	0
• Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	0
• Natalizumab (Tysabri and Tyruko)	0

7 of the patients identified in question 2 are receiving treatment from UHSussex.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm